Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1/2 2

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Lymphoid 2Head & Neck 2Other hematologic neoplasm 1Other 1Myeloid 1

Conditions

Neoplasms 2Head and Neck Neoplasms 2Stomatitis 1Mucositis 1

Interventions

pembrolizumab 65Cisplatin 42Cetuximab 36Radiotherapy 28Nivolumab 26Paclitaxel 22Carboplatin 22Docetaxel 20durvalumab 14Radiotherapy, Intensity-Modulated 12Fluorouracil 12Cyclophosphamide 11tremelimumab 9Gemcitabine 9Ipilimumab 8fludarabine 7avelumab 7Erlotinib Hydrochloride 7toripalimab 6epacadostat 6cemiplimab 6Radiosurgery 6Interleukin-2 6Capecitabine 6Bevacizumab 6spartalizumab 5Celecoxib 5zalutumumab 4tislelizumab 4fludarabine phosphate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Fibroblast Growth Factor 7 × Head & Neck × Clear all
NCT00626639 2017-06-21

A Study of Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy and Concurrent Chemotherapy

Swedish Orphan Biovitrum

Phase 1/2 Completed
5 enrolled 8 charts
Head & NeckOther

Head and Neck Neoplasms, Neoplasms, Mucositis

NCT00540332 2009-03-02

A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy

Swedish Orphan Biovitrum

Phase 1/2 Withdrawn
Head & Neck

Head and Neck Neoplasms, Neoplasms, Stomatitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡